Dihua Yu

Active 1990–2025

125
Papers
26,678
Citations
84
h-index
121
i10-index

Citations

Citations per year for Dihua Yu1991: 4 citations1992: 6 citations1993: 7 citations1994: 7 citations1995: 12 citations1996: 5 citations1997: 15 citations1998: 24 citations1999: 38 citations2000: 75 citations2001: 82 citations2002: 106 citations2003: 123 citations2004: 118 citations2005: 144 citations2006: 157 citations2007: 179 citations2008: 169 citations2009: 203 citations2010: 228 citations2011: 283 citations2012: 281 citations2013: 261 citations2014: 243 citations2015: 217 citations2016: 204 citations2017: 225 citations2018: 253 citations2019: 744 citations2020: 873 citations2021: 929 citations2022: 922 citations2023: 933 citations2024: 1,447 citations2025: 796 citations2026: 21 citations

Citation sources

Countries

World map of the countries and regions citing this authorChina: 3,599 citing papers, 28.6% of this breakdownUnited States: 3,223 citing papers, 25.6% of this breakdownUnited Kingdom: 437 citing papers, 3.5% of this breakdownItaly: 429 citing papers, 3.4% of this breakdownGermany: 407 citing papers, 3.2% of this breakdownCanada: 286 citing papers, 2.3% of this breakdownJapan: 278 citing papers, 2.2% of this breakdownSouth Korea: 275 citing papers, 2.2% of this breakdownFrance: 258 citing papers, 2% of this breakdownSpain: 253 citing papers, 2% of this breakdownIndia: 252 citing papers, 2% of this breakdownTaiwan: 249 citing papers, 2% of this breakdown
0%28.6%Other 21%

Fields

  • Biochemistry, Genetics and Molecular Biology46.8%
  • Medicine40.5%
  • Immunology and Microbiology7%
  • Engineering1.5%
  • Neuroscience1.2%
  • Computer Science0.6%
  • Other2.4%

Topics

  • Extracellular vesicles in disease3.9%
  • MicroRNA in disease regulation3.6%
  • Cancer Immunotherapy and Biomarkers3.6%
  • HER2/EGFR in Cancer Research3.2%
  • Cancer-related molecular mechanisms research2.7%
  • Cancer Cells and Metastasis2.5%
  • Other80.5%

Coauthors

All papers

Open in search
  1. Tumor microenvironment as a therapeutic target in cancer

    Authors: , - Pharmacology & Therapeutics 2020 cited by 1,958

  2. Exosomes in cancer development, metastasis, and immunity

    Authors: , - Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2019 cited by 991

  3. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Nature Communications 2016 cited by 1,110

  4. Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy

    Authors: , , , , , , , , , , , , , , , , - Nature Communications 2021 cited by 605

  5. TYRO3 induces anti–PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis

    Authors: , , , , , , , , , , , , , , , , - Journal of Clinical Investigation 2021 cited by 313

  6. Deubiquitination and Stabilization of PD-L1 by CSN5

    Authors: , , , , , , , , , , , , , , , , , , , , , - Cancer Cell 2016 cited by 767

  7. Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth

    Authors: , , , , , , , , , , , , , , , , , , , , , - Nature 2015 cited by 1,170

  8. Targeting the αv integrin/TGF-β axis improves natural killer cell function against glioblastoma stem cells

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Corry M. Jones, Mustafa Bdiwi, Ana Karen Nunez Cortes, Enli Liu, Jun Yu, Nobuhiko Imahashi, Luis Muniz-Feliciano, Ye Li, Jian Hu, Giulio Draetta, David Marín, Dihua Yu, Stephan Mielke, Matthias Eyrich, Richard E. Champlin, Ken Chen, Frederick F. Lang, Elizabeth J. Shpall, Amy B. Heimberger, Katayoun Rezvani - Journal of Clinical Investigation 2021 cited by 252

  9. The allergy mediator histamine confers resistance to immunotherapy in cancer patients via activation of the macrophage histamine receptor H1

    Authors: , , , , , , , , , , , , , , , , , , , - Cancer Cell 2021 cited by 305

  10. EZH2 engages TGFβ signaling to promote breast cancer bone metastasis via integrin β1-FAK activation

    Authors: , , , , , , , , , , - Nature Communications 2022 cited by 192

  11. The impact of PD-L1 N-linked glycosylation on cancer therapy and clinical diagnosis

    Authors: , , , , - Journal of Biomedical Science 2020 cited by 193

  12. Activated T cell-derived exosomal PD-1 attenuates PD-L1-induced immune dysfunction in triple-negative breast cancer

    Authors: , , , , , , , , , , , - Oncogene 2021 cited by 142

  13. Vitamin E Enhances Cancer Immunotherapy by Reinvigorating Dendritic Cells via Targeting Checkpoint SHP1

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Cancer Discovery 2022 cited by 125

  14. Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Lieping Chen, Dihua Yu, Mien‐Chie Hung, Michael A. Curran, Leng Han, Chunru Lin, Liuqing Yang - Nature Immunology 2019 cited by 369

  15. ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Cell Biology 2008 cited by 699

  16. The Skp2-SCF E3 Ligase Regulates Akt Ubiquitination, Glycolysis, Herceptin Sensitivity, and Tumorigenesis

    Authors: , , , , , , , , , , , , , , , , - Cell 2012 cited by 468

  17. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients

    Authors: , , , , , , , , , , , , - Cancer Cell 2004 cited by 1,868

  18. Blocking immunosuppressive neutrophils deters pY696-EZH2–driven brain metastases

    Authors: , , , , , , , , , , , , , , , , - Science Translational Medicine 2020 cited by 119

  19. Photothermal and Acid-Responsive Fucoidan-CuS Bubble Pump Microneedles for Combined CDT/PTT/CT Treatment of Melanoma

    Authors: , , , , , , - ACS Applied Materials & Interfaces 2023 cited by 62

  20. Tumor-associated nonmyelinating Schwann cell–expressed PVT1 promotes pancreatic cancer kynurenine pathway and tumor immune exclusion

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Liuqing Yang - Science Advances 2023 cited by 58

  21. Hormonal therapies up-regulate MANF and overcome female susceptibility to immune checkpoint inhibitor myocarditis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Chunru Lin - Science Translational Medicine 2022 cited by 56

  22. Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways

    Authors: , , , , , , , , , , , , , - Nature Medicine 2011 cited by 517

  23. JAK2-binding long noncoding RNA promotes breast cancer brain metastasis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Investigation 2017 cited by 231

  24. Brain metastasis: Unique challenges and open opportunities

    Authors: , - Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2016 cited by 169